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Background:  HIV-exposed  uninfected  infants  have  increased  infection  risk  and  mortality  compared  to
HIV-unexposed  infants.  HIV-exposed  infants  may  be at  increased  risk  of  invasive  GBS  disease  due to
reduced  maternal  antibody  against  GBS.
Methods: We  quantiﬁed  antibodies  that  bind  to  the surface  of  whole  Group  B Streptococcus  (GBS) of
serotypes  Ia,  Ib,  II, III and  V  using  novel  ﬂow  cytometry  assays  in  South  African  HIV-infected  and  non-
infected  mothers  and  their  uninfected  infants.  Antibody-mediated  complement  C3b/iC3b  deposition  onto
GBS of  these  serotypes  was  also  quantiﬁed  by a novel  ﬂow  cytometry  assay.
Results: Geometric  mean  concentration  (GMC)  of  both  surface-binding  anti-GBS  antibody  and  antibody-
mediated  complement  deposition  onto  GBS  were reduced  in  HIV-infected  women  (n = 46)  compared  to
HIV-uninfected  women  (n  =  58)  for ST1a  (surface-binding:  19.3 vs  29.3;  p  =  0.003;  complement  depo-
sition:  2.9  vs  5.3  SU/mL;  p = 0.003),  STIb  (24.9  vs  47.6;  p =  0.003;  2.6 vs  4.9  SU/mL;  p =  0.003),  STII (19.8
vs  50.0;  p = 0.001;  3.1 vs  6.2 SU/mL; p = 0.001),  STIII  (27.8  vs  60.1;  p = 0.001;  2.8 vs  5.3 SU/mL;  p =  0.001)
and  STV (121.9  vs  185.6 SU/mL;  p  <  0.001)  and  in  their infants  for STIa  (complement  deposition  9.4 vs
27.0  SU/mL;  p = 0.02),  STIb  (13.4  vs  24.5  SU/mL;  p = 0.02),  STII (14.6  vs  42.7 SU/mL;  p  = 0.03),  STIII  (26.6 vs
62.7  SU/mL;  p = 0.03)  and  STV  (90.4 vs  165.8  SU/mL;  p = 0.04).  Median  transplacental  transfer  of antibody
from  HIV-infected  women  to their  infants  was reduced  compared  to HIV-uninfected  women  for  GBS
serotypes  II (0.42  [IQR  0.22–0.59]  vs 1.0  SU/mL  [0.42–1.66];  p < 0.001),  III (0.54  [0.31–1.03]  vs  0.95  SU/mL
[0.42–3.05],  p  =  0.05)  and V  (0.51  [0.28–0.79]  vs  0.75  SU/mL  [0.26–2.9],  p =  0.04).  The differences  between
infants  remained  signiﬁcant  at 16  weeks  of age.
Conclusions:  Maternal  HIV  infection  was  associated  with  lower  anti-GBS  surface  binding  antibody  con-
centration  and  antibody-mediated  C3b/iC3b  deposition  onto  GBS  bacteria  of serotypes  Ia,  Ib,  II,  III and  V.
This  may  render  these  infants  more  susceptible  to  early  and  late onset  GBS  disease.
 201Crown  Copyright  ©
. IntroductionThe increasing numbers of HIV-exposed infants who remain
ninfected is testament to the success of prevention of mother-to-
hild transmission programs in resource-poor settings in the face
 Preliminary data was presented at the European Society of Infectious Diseases
eeting May  2014, Dublin, Ireland.
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of a high disease burden [1]. Nevertheless, this group of infants
appears to suffer from increased rates of lower respiratory tract
infection and meningitis compared to HIV-unexposed infants and
up to 4-fold higher mortality in the ﬁrst year of life [2–4]. Strepto-
coccus agalactiae (group B streptococcus, GBS) is a leading cause of
neonatal pneumonia, sepsis and meningitis in many countries and
ﬁve serotypes (Ia, Ib, II, III and V) account for the majority of disease
[5]. Published data show that not only is GBS carriage increased
in HIV-infected pregnant women  compared with HIV-uninfected
mothers [6], but that HIV-exposed, uninfected infants also appear
to have an increased risk of late-onset GBS disease compared to
HIV-unexposed infants [7].
icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Prevention of GBS infection in infants and adults through immu-
ization is a theoretically attainable goal. Maternal transfer of
ntibodies is thought to prevent newborn GBS disease [8] and
BS vaccines offer the potential to prevent disease in low-income
ettings where prenatal screening and intrapartum antibiotics are
enerally not feasible. A number of studies have demonstrated
n association between the risk of developing invasive GBS dis-
ase in the newborn and maternal anti-capsular antibody levels
9–12] with opsonophagocytosis the likely effector mechanism
13–15]. However, maternal HIV status can inﬂuence the efﬁ-
iency of transplacental antibody transfer, resulting in reduced
aternally-derived speciﬁc antibody concentration in the infant,
ven where the infant is subsequently HIV uninfected [16–19].
ata regarding the persistence of anti-GBS antibodies in popula-
ions with high HIV-prevalence and their function in vitro would
rovide insight into their protective potential in different popula-
ions. Thus our objective was to determine the association between
aternal HIV infection status and total IgG binding to the surface of
BS bacteria of serotypes Ia, Ib, II, II and V and antibody-mediated
eposition of C3b/iC3b onto the surface of these GBS strains as a
otential surrogate for opsonophagocytosis in sera obtained from
others and infants.
. Methods
.1. Study setting, eligibility and study measures
Samples were collected from mothers and infants enrolled in
 cohort study investigating the inﬂuence of maternal HIV and
ycobacterial sensitization on infant immune responses to BCG
accination carried out between 2009 and 2011 [20]. In brief, 109
regnant women presenting to a Community Health Center in
hayelitsha, Western Cape Province, South Africa who  delivered
 healthy infant over 37 weeks gestation, weighing over 2.5 kg,
new the result of their HIV test and were willing to provide
ritten informed consent for themselves and their infants were
ecruited to the original study. The subset represented all moth-
rs/infants with available samples. A venous blood sample was
ollected from the mother and infant within 24 h of delivery.
ll infants had a further venous blood sample collected at 16
eeks. HIV-exposed infants had an HIV polymerase chain reaction
Amplicor HIV-a DNA kit, version 1.5; Roche Molecular Systems
nc., Branchburg, NJ) performed at ages 4 and 16 weeks. The study
as approved by the Universities of Cape Town (382/2008) and
tellenbosch (N08/10/278), South Africa, and the National Health
ervice Research Ethics Committee, England (07/H0720/178).
In 2009, the HIV prevalence among women attending antenatal
linics in the area was 31% [21]. During the study period, the Pre-
ention of Mother to Child Transmission program consisted of dual
herapy for mothers and infants, starting with the administration
f zidovudine at 28 or more weeks’ gestation, then zidovudine for 1
onth to the infant and a single dose of nevirapine to both mother
nd infant. Mothers were eligible for highly active antiretroviral
reatment if their CD4 count was less than 200 cells/L. Exclu-
ive infant feeding options were encouraged and mothers were
rovided with free formula for 6 months if they chose exclusive
ormula feeding.
.2. Laboratory assaysThe reproducibility of the assays was assessed between three
ifferent days and between three different operators with a panel
f 18 sera. The assays had a coefﬁcient of variation of less than
0%. Controls used were rabbit polyclonal sera (SSI) raised against
erotypes Ia, Ib, II, III & V, and normal human donor sera. 33 (2015) 621–627
2.2.1. GBS isolates and growth conditions
Group B Streptococcus isolates used in this study were
H092040676 (Serotype Ia), H090820125 (Serotype Ib),
H090320548 (Serotype II), H092120162 (Serotype III) and
H091780506 (Serotype V), which were kindly provided by
Professor Androulla Efstratiou, Public Health England, Colindale.
Strains are subsequently referred to by their serotype.
GBS isolates used in the antibody surface binding and comple-
ment deposition assays were grown in Todd Hewitt broth at 37 ◦C
with shaking (200 rpm). Once OD600nm 1.0 was reached, cultures
were centrifuged at 3060 × g for 5 min  to pellet the bacteria. The
pellet was  re-suspended in the same volume of phosphate buffered
saline (PBS, pH 7.4, Severn Biotech, UK) containing 2% formalde-
hyde and incubated at room temperature for 1 h. Bacteria were
then washed in PBS by three rounds of centrifugation at 3060 × g
for 5 min  and resuspended. The ﬁnal cell pellet was resuspended in
1 mL  PBS, which was stored at 4 ◦C before use.
2.2.2. Sample preparation for antibody surface binding assay
Deposition of anti-GBS antibody onto the surface of whole
GBS bacteria was  measured on formaldehyde-ﬁxed GBS using a
ﬂow cytometric assay performed in 96-well microtitration plates.
Brieﬂy, 2 L of each test serum was  added to 198 L of serotype Ia,
Ib, II, III or V GBS bacteria at 5.14 × 107 CFU/mL in blocking buffer
(1% BSA in PBS). This was incubated at 25 ◦C for 30 min with shaking
(900 rpm), then pelleted. Supernatant was removed and the pel-
let washed twice with 200 L of blocking buffer. Alexa Fluor® 488
Goat Anti-Human IgG (H&L) (Life Technologies) (1:500) in blocking
buffer was added and samples incubated for 20 min  at 4 ◦C, before
being washed twice more with blocking buffer.
2.2.3. Sample preparation for antibody-mediated complement
C3b/iC3b deposition assay
Antibody-mediated C3b/iC3b deposition on the surface of whole
GBS bacteria was measured on the surface of formaldehyde-ﬁxed
GBS using a ﬂow cytometric assay performed in 96-well microtitra-
tion plates. Brieﬂy, 35 L serotype Ia, Ib, II, III and V GBS bacteria at
5.14 × 107 CFU/mL in blocking buffer (1% BSA in PBS) were added
to 10 L IgG-depleted human complement [22] and 5 L of each
test serum. Plates were incubated for 7.5 min  at 37 ◦C with shak-
ing (900 rpm) then pelleted. Supernatant was removed and the
pellet washed once with 200 L blocking buffer. Samples were
resuspended in 200 L blocking buffer containing 1:500 sheep anti-
human C3c FITC (Abcam) and incubated as for the surface binding
assay.
2.2.4. Sample acquisition
Assays were analyzed using a Beckman Coulter Cyan ﬂow
cytometer equipped with a Cytek 96-well microtitre plate reader.
Protocols were initially set-up to analyze proﬁles of bacterial events
using bacteria-only control samples and the bacteria identiﬁed on
the cytometer by the forward scatter (FS), measuring the size of the
cell, and side scatter (SS), the granularity and internal structural
complexity. An analysis ‘gate’ was  drawn around the population
of interest (single and diplococci) and a relevant histogram plot
created to analyze the ﬂuorescence of the bacterial population.
For each sample, 10,000 individual events were analyzed for ﬂu-
orescence and a horizontal gate was  drawn to include 10% of the
‘no antibody’ control population. A ﬂuorescence index (FI) was
calculated for each sample, which involved the multiplication of
the percentage of bacteria in the horizontal gate (%-gated), by the
mean ﬂuorescence of that population (X-mean). The ﬁnal result
for each test was expressed as the average FI of duplicate test
samples minus the average FI of the bacteria and conjugate-only
control. A standard unit (SU) measurement for each serum sam-
ple was then calculated by comparing to the serum FI response
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Fig. 1. Reverse cumulative distribution curve of maternal anti-GBS IgG surface bind-
ing by serotype concentrations (SU/mL). Curve demonstrates the percentage of theK. Le Doare et al. / Va
btained with the positive control serum for each serotype which
as given an arbitrary value of 1000 (kind gift from Professor
arol Baker, Baylor College of Medicine, Texas) to give a result in
U/mL.
.3. Data management and statistical analysis
Sample size was determined for the cohort study; this sub-study
ad 80% power (p = 0.05) to investigate differences between anti-
ody concentrations in HIV-exposed and HIV-unexposed infants
f at least 30% with the pre-speciﬁed hypothesis that the con-
entrations would be lower in HIV-exposed infants. This assay is
urrently being formally compared with ELISA and opsonophago-
ytosis uptake assays in another study.
Statistical analyzes were completed using STATA version 12
StataCorp 2013, La Jolla, CA) and GraphPad Prism version 6.0
GraphPad Software Inc., La Jolla, CA). Due to the skewed distribu-
ion of the anti-GBS antibody concentrations, log transformations
ere required to conform to regression assumptions. A paired t-test
as used to determine any difference in anti-GBS-antibody con-
entrations to each GBS serotype between birth and at 16 weeks.
omparison of infant anti-GBS antibody concentrations by mater-
al HIV status was calculated using the Wilcoxon rank sum test.
orrelation of infant anti-GBS antibody concentration to each GBS
erotype at birth and at 16 weeks was assessed using Spearman
orrelation. Multiple linear regression was used to ascertain the
elationship between infant anti-GBS antibody concentration to
ach GBS serotype and the covariates of maternal age, infant sex
nd maternal HIV. In addition, multiple linear regression was used
o explore the relationship between maternal anti-GBS antibody
oncentration to each serotype and the covariates maternal age,
aternal HIV status. Placental transfer was deﬁned as the ratio
f infant-to-mother anti-GBS IgG concentration at birth. Missing
ata were excluded from analysis. Decline in antibody concentra-
ion between birth and 16 weeks was calculated using ratio of
eans.
. Results
.1. Participant characteristics
Samples were analyzed from 104 women (46 (44%) HIV-infected
nd 58 (56%) HIV-uninfected women) and from 100 infants born to
his group of women (46 (46%) HIV-exposed and 54 (54%) HIV-
nexposed infants). One mother–infant pair was  excluded from
he ﬁnal analysis because HIV-infection in the infant was  detected
t 4 weeks of age and the infant was referred for rapid initiation
f antiretroviral treatment. All other infants born to HIV-infected
others were HIV-uninfected. All infants were born after 37 weeks
estation. Follow-up samples at 16 weeks were available for 93
nfants (93%; 38 HIV-exposed and 55 HIV-unexposed) at a mean
ostnatal age of 16.4 weeks (SD = 1.7).
All HIV-infected women chose exclusive formula replacement
eeding. The median (IQR) CD4 count among the HIV-infected
omen was 411.5 (293.9–604.0) cells/L and the median (IQR)
iral load was 800 (357–6000) copies/mL Seven women had CD4
ounts of less than 200 cells/L; three of these were taking
ighly active antiretroviral treatment at enrollment and four were
eferred to commence highly active antiretroviral treatment fol-
owing delivery. Further characteristics of the study cohort have
een described previously [20]. At the time of the study, local
BS disease incidence in Cape Town was reported at 0.67/1000
ive births in a population with 24% of these infants being HIV-
ninfected, born to HIV-infected mothers [23].total population with each antibody concentration for each of the ﬁve GBS serotypes.
ST,  serotype; SU/mL, standard units/mL
3.2. Maternal anti-GBS-antibody to GBS serotypes Ia, Ib, II, III and
V
All maternal sera had measurable geometric mean concentra-
tions (GMC) of antibody to at least one serotype. The distribution
of mothers’ antibodies that bound to the surface of GBS serotypes
Ia, Ib, II, III and V is shown in Fig. 1. The predominant surface bind-
ing anti-GBS-antibody was  against serotype V, followed by II, III, Ib
and Ia (Fig. 1).
Women  with HIV infection had signiﬁcantly lower GMC  anti-
body concentrations to all ﬁve serotypes at delivery compared to
HIV-uninfected women (Fig. 2 and Table 1). There were no asso-
ciations between CD4 count and viral load on anti-GBS antibody
concentration by serotype in HIV-infected women.
The concentrations of antibody-mediated complement
C3b/iC3b deposition by GBS serotype are shown in Table 2.
The GMC  of antibody-mediated C3b/iC3b deposition was  signiﬁ-
cantly greater in HIV-uninfected than HIV-infected women  for all
serotypes. The GMC  of antibody-mediated C3b/iC3b deposition
ranged from 4.9 SU/mL (serotype III) to 6.17 SU/mL  (serotype V)
in HIV-uninfected women  and from 2.6 SU/mL (serotype Ib) to
3.4 SU/mL (serotype V) in HIV-infected women.
3.3. Association of maternal HIV infection with placental transfer
of anti-GBS antibody
There was a positive correlation between paired maternal and
infant surface binding antibody concentrations for all serotypes (Ia,
r2 = 0.63, p < 0.001; Ib, r2 = 0.71, p < 0.001; II, r2 = 0.17, p < 0.001; III,
r2 = 0.35, p < 0.001; V, r2 = 0.16, p < 0.001). HIV-infected women had
signiﬁcant reductions in placental transfer of anti-GBS serotypes II
and V compared with HIV-uninfected women (Table 3). There was
no association between CD4 count or viral load on transplacental
transfer ratios.
3.4. Infant anti-GBS-antibody by serotype at birth to GBS
serotypes Ia, Ib, II, III and V
HIV-exposed uninfected infants had signiﬁcantly lower GMCs
of anti-GBS surface binding antibodies to all serotypes than unex-
posed infants (Fig. 3 and Table 1). In a multiple regression model
maternal HIV-status remained signiﬁcant (p < 0.05).However, there were no signiﬁcant associations found between
infant anti-GBS-antibody concentrations to each serotype and
maternal age or infant sex.
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Fig. 2. Maternal anti-GBS surface binding IgG to GBS serotypes Ia, Ib, II, III and V concentrations at delivery (SU/mL). ST indicates GBS serotype. HIV indicates human
immunodeﬁciency virus. Horizontal lines indicate GMC  response.
Table 1
Geometric mean surface binding antibody concentrations (95% conﬁdence intervals) in HIV-infected and HIV-uninfected mothers and their infants at birth and at 16 weeks
of  age.
STIa STIb STII STIII STV
HIV+ mother 19.3 (12.7–29.3) 24.9 (19.6–31.6) 21.8 (13.4–35.7) 27.8 (15.9–48.6) 121.9 (88.0–169.0)
HIV−  mother 37.0 (24.8–55.2) 47.6 (33.3–68.1) 50.0 (28.7–87.0) 60.1 (36.0–100.5) 185.6 (126.4–272.4)
HIV-exposed infants (birth) 9.4 (6.1–14.5) 13.4 (9.6–18.7) 14.6 (8.1–26.3) 26.6 (17.8–39.8) 90.4 (61.16–133.6)
HIV-unexposed infants (birth) 27.0 (16.5–44.3) 24.5 (16.4–36.5) 42.7 (23.4–77.8) 62.7 (38.1–103.1) 165.8 (112.0–245.4)
HIV-exposed infants (16 w) 7.0 (3.8–13.0) 8.7 (6.3–12.1) 17.6 (8.5–36.3) 48.0 (28.3–81.3) 68.54 (38.0–123.6)
HIV-unexposed infants (16 w)  21.6 (13.6–34.2) 14.9 (10.6–21.1) 68.3 (38.8–120.3) 97.4 (63.0–150.7) 180.2 (106.3–305.4)
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected; 16 w,  16 weeks of
age.
Table  2
Geometric mean concentration of antibody-mediated C3b/iC3b deposition (95% conﬁdence intervals) on GBS serotypes Ia, Ib, II, III and V in HIV-infected and HIV-uninfected
mothers and their infants at birth.
STIa p value STIb p value STII p value STIII p value STV p value
HIV+ mother 2.9 (2.3–3.6) 2.6 (1.9–3.2) 3.1 (2.4–3.9) 2.8 (2.2–3.6) 3.4 (2.8–4.2)
HIV−  mother 5.3 (4.6–6.2) 0.003 4.9 (4.2–5.4) 0.003 6.2 (5.6–6.8) 0.001 5.3 (4.5–6.2) 0.001 6.2 (4.9–6.9) <0.0001
HIV-unexposed infants 6.1 (5.9–6.3) 5.9 (4.6–6.2) 6.9 (5.6–7.2) 6.6 (6.4–6.7) 6.3 (5.8–6.9)
HIV-exposed infants 3.8 (3.0–4.8) 0.02 3.1 (3.0–4.1) 0.02 4.2 (3.9–4.9) 0.02 3.9 (3.1–5.0) 0.03 4.2 (3.3–5.4) 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected.
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Table  3
Inﬂuence of maternal HIV-infection on transplacental transfer of anti-GBS surface binding antibody to GBS serotypes Ia, Ib, II, III and V.
GBS serotype HIV-infected mothers: infants (IQR) HIV-uninfected mothers: infants (IQR) % Reduction in HIV-infected p value
STIa 0.66 (0.34–0.99) 0.6 (0.39–0.96) 0% 0.86
STIb  0.48 (0.17–0.88) 0.52 (0.32–0.78) 8% 0.48
STII  0.42 (0.22–0.59) 1.0 (0.42–1.66) 58% <0.001
STIII  0.54 (0.31–1.03) 0.95 (0.4–3.05) 43% 0.05
STV  0.51 (0.28–0.79) 0.75 (0.26–2.9) 32% 0.04
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iTIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS ser
ninfected; 16 w,  16 weeks of age.
Signiﬁcantly lower GMC  of antibody-mediated C3b/iC3b depo-
ition was noted amongst HIV-exposed infants compared to
IV-unexposed infants for all serotypes (Table 2). Notably, the GMC
f antibody-mediated C3b/iC3b deposition was higher in infants
han in their mothers for all serotypes..5. Infant anti-GBS antibody at 16 weeks of age
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unexposed infants for all serotypes (Table 1). HIV-exposed infants
had signiﬁcantly slower median rate of antibody decline com-
pared to HIV-unexposed infants at 16 weeks compared to birth to
STII (ratio of decline 1.03 [IQR −0.35 to 4.6] vs 0.21 SU/mL [−0.62
to 0.54], p = 0.04) and STIII (1.53 [−0.21 to 5.36] vs −0.09 SU/mL
(−0.60 to 0.93), p = 0.03) but not to ST1a (−0.12 [IQR −0.64 to
0.13] vs −0.04 [−0.39 to 0.45]), ST1b (−0.52 [−0.65 to 0.46]
vs −0.36 [−0.18 to 0.74]) or STV (−0.40 [−0.61 to 2.9] vs 0.14
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. Discussion
Our ﬁndings demonstrate that total surface binding and func-
ional maternal antibody concentration to each of the GBS
erotypes (Ia, Ib, II, III and V) is lower at delivery in HIV-infected
omen compared to their HIV-uninfected peers. Further, for three
f the ﬁve serotypes (II, III, V) the transplacental transfer ratio
as signiﬁcantly lower from HIV-infected women to their unin-
ected infants. It follows therefore that infants born to HIV-infected
omen had lower anti-GBS surface binding antibody concentra-
ions at birth for all serotypes; this difference was still evident at
6 weeks of age. The implication of our ﬁndings is that HIV-exposed
nfants may  be more vulnerable to early and late onset GBS disease
han infants born to HIV-uninfected mothers.
Rectovaginal colonization with GBS is more frequent in HIV-
nfected women compared to HIV-uninfected women [6,24].
aternal colonization is the major risk factor for infant acquisi-
ion at birth and for early onset GBS disease. Thus infants born
o HIV infected mothers may  have both increased susceptibility
nd increased exposure. It is generally understood that mater-
al colonization stimulates maternal immunity; thus the ﬁnding
f lower maternal antibody concentrations despite higher colo-
ization rates suggests impairment of anti-GBS-speciﬁc antibody
roduction. This is also seen with polysaccharide-speciﬁc antibody
roduction in HIV-infected adults, such as in pneumococcal dis-
ase [25]. The fact that HIV-infected women have higher rates of
BS colonization than HIV-uninfected women may  mean that anti-
ody production secondary to colonization with GBS is deﬁcient in
he context of maternal HIV-infection increasing the risk of invasive
BS disease in HIV-exposed infants.
It is difﬁcult to correlate our anti-GBS antibody results with what
s known regarding maternal colonization and infant GBS disease in
his South African population. However, the highest concentrations
f antibodies in women at delivery were to STV and III bacteria. The
atter is consistent with the known predominance of STIII among
arried strains in South African women (37%) but STV is carried by
 minority of women (10%) [24,26]. In our cohort the lowest lev-
ls of antibody were to STIa bacteria, which is consistent with an
ncreased incidence of disease due to this serotype [26]. Our ﬁnd-
ngs may  suggest differences in the immune response to different
olonizing serotypes.
It is likely that lower maternal antibody concentrations and
ltered transplacental transfer of antibody in HIV infection play a
ole in the increased susceptibility to infectious diseases in infancy
19,27], but there is a lack of data on the impact of maternal HIV
nfection on neonatal infections in general, including GBS infec-
ions [28]. Infant anti-GBS surface binding antibody by serotype
emains lower at 16 weeks in HIV-exposed, uninfected infants,
ho might therefore be more vulnerable to late onset GBS disease.
his corresponds to recent data from Cape Town which suggest
hat 56% of GBS disease occurred after 7 days of life in a popula-
ion where one in four infants were HIV-exposed [23]. Apart from
he reduced passive immunity provided by maternal antibody in
he context of maternal HIV infection it might be that there are
ifferences in the immune response to infection of HIV-exposed,
ninfected infants secondary to in utero HIV exposure, as some data
uggest that these infants have altered lymphocyte differentiation
nd function despite remaining HIV-uninfected [29,30]. However,
ow this corresponds to clinical infection in the neonatal period is
ot known.
Our ﬁndings are consistent with studies that demonstrate the
igher risk of infectious morbidity and mortality in HIV-exposed
nfants compared to HIV-unexposed infants [31–33]. Recent South
frican studies demonstrated a high prevalence of neonatal GBS
isease in a population with a high HIV burden [23,24,34]. A Study
rom Malawi also demonstrated high rates of early and late onset 33 (2015) 621–627
GBS infection in a population with high HIV prevalence [35]. In
contrast, one study from the USA did not ﬁnd evidence of increased
susceptibility to GBS infection in HIV-exposed, uninfected infants
suggesting either regional screening and treatment differences
for both HIV infection and GBS carriage or population-based dif-
ferences in late onset GBS disease that might be unrelated to
HIV-status [36].
Our study has some limitations. Firstly, we  did not assess col-
onization in the mothers participating in the study and thus were
unable to correlate antibody responses to maternal colonization.
Whilst no infant developed early or late onset sepsis or meningitis
during the study, our sample size was also too small to detect this
as a valid endpoint and this was  not the aim of the study.
The use of two novel ﬂow cytometric assays that quantify anti-
body binding to the surface of GBS bacteria and antibody-mediated
C3b/iC3b deposition on the bacterial surface may provide a more
complete assessment of antibody function than the measurement
of anti-polysaccharide IgG alone. However, the response measured
is not wholly serotype-speciﬁc as part of the antibody binding is
to cell wall proteins as well as the polysaccharide capsule. Despite
this, we see a serotype-speciﬁc response with a clear differentia-
tion between the distribution of antibody binding to the different
serotypes.
The potential of a trivalent maternal GBS vaccine encompass-
ing the major disease-causing serotypes (Ia, Ib, III) [8] to protect
against neonatal disease remains promising. However, it is vital
that ongoing evidence to support its use in vulnerable populations
with high HIV-prevalence is collected in order to support immu-
nization strategies in Sub-Saharan Africa.
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